Search Result
Results for "
Metallo-β-lactamase
" in MedChemExpress (MCE) Product Catalog:
1
Biochemical Assay Reagents
5
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0368
-
|
SQ 14225
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-13271A
-
Tubastatin A
Maximum Cited Publications
38 Publications Verification
|
Beta-lactamase
HDAC
Autophagy
Apoptosis
|
Cancer
|
|
Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
-
- HY-13428
-
|
|
Beta-lactamase
HDAC
Virus Protease
|
Cancer
|
|
Tubacin is a potent and selective inhibitor of HDAC6, with an IC50 value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
-
- HY-10990
-
|
CRA 024781; PCI-24781
|
HDAC
|
Cancer
|
|
Abexinostat (CRA 024781) is a novel pan-HDAC inhibitor mostly targeting HDAC1 with Ki of 7 nM. Abexinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
|
-
-
- HY-13322
-
|
SB939
|
Beta-lactamase
HDAC
Apoptosis
|
Cancer
|
|
Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
|
-
-
- HY-13271
-
|
Tubastatin A HCl; TSA HCl
|
Beta-lactamase
HDAC
Autophagy
Apoptosis
|
Cancer
|
|
Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
-
- HY-P0267
-
-
-
- HY-106178
-
PMX-53
Maximum Cited Publications
8 Publications Verification
3D53
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .
|
-
-
- HY-19328
-
ACY-775
2 Publications Verification
|
HDAC
|
Cardiovascular Disease
Neurological Disease
|
|
ACY-775 is a potent and selective inhibitor of the of histone deacetylase 6 (HDAC6) with an IC50 of 7.5 nM . ACY775 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
|
-
-
- HY-18678A
-
|
PT-141 Acetate
|
Melanocortin Receptor
|
Metabolic Disease
|
|
Bremelanotide (PT-141) Acetate is a melanocortin receptor agonist. Bremelanotide Acetate can activate MC4R and increases dopamine release. Bremelanotide Acetate induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide Acetate can be used for the research of hypoactive sexual desire disorders .
|
-
-
- HY-P0227
-
|
|
Melanocortin Receptor
|
Metabolic Disease
|
|
SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC50 values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.
|
-
-
- HY-148493
-
|
|
Bacterial
|
Infection
|
|
MK-3402 (Compound303) is a metallo-beta-lactamase inhibitor, with IC50 values of 0.53, 0.25 and 0.169 nM against IMP-1, NDM-1, and VIM-1, respectively. MK-3402 can be used in bacterial research and shows a synergistic effect when used in combination with beta-lactam antibiotics .
|
-
-
- HY-100871
-
|
|
Beta-lactamase
HDAC
Apoptosis
|
Cancer
|
|
WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
|
-
-
- HY-121765
-
|
N,S-Diacetyl-L-cysteine
|
Endogenous Metabolite
|
Metabolic Disease
|
|
Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
|
-
-
- HY-P11290
-
-
-
- HY-B0368R
-
|
SQ 14225 (Standard)
|
Reference Standards
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (Standard) is the analytical standard of Captopril. This product is intended for research and analytical applications. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-136306
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-beta-lactamase ligand 1 is a class B β-lactamase inhibitor with antibacterial activity extracted from patent WO2019221122A1, compound A .
|
-
-
- HY-144659
-
|
|
Beta-lactamase
Apoptosis
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-5 (compound 5c) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-5 shows inhibitory activity against MBLs NDM-1 and VIM-1. Metallo-β-lactamase-IN-5 inhibits HUVECs with an IC50 of 45 μg/mL. Metallo-β-lactamase-IN-5 plus Imipenem exhibits synergistic antimicrobial activity .
|
-
-
- HY-W101299
-
|
|
Amino Acid Derivatives
|
Metabolic Disease
|
|
N-Acetyl-D-allo-isoleucine is an amino acid derivative. N-Acetyl-D-allo-isoleucine is promising for research of amino acid metabolism, such as abnormal isoleucine metabolism .
|
-
-
- HY-P1208
-
|
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
PG-931, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R (IC50=2.4 nM). PG-931 can reverse haemorrhagic shock and prevent multiple organ damage in vivo .
|
-
-
- HY-163338
-
|
|
Beta-lactamase
|
Infection
|
|
Metallo-β-lactamase-IN-13 (Compound 13i) is a pan Metallo-β-Lactamase inhibitor. Metallo-β-lactamase-IN-13 provides broader coverage of metallo-β-lactamases expressing Gram-negative (GN) bacteria. Metallo-β-lactamase-IN-13 has antibacterial activity against P. aeruginosa .
|
-
-
- HY-B0967
-
|
|
Antibiotic
Bacterial
|
Infection
|
|
Phthalylsulfacetamide is an orally active sulfonamide antibiotic and New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 15.4 μM. Phthalylsulfacetamide stably binds to the active hydrolysis center of NDM-1, interacts with Zn2+, and interacts with key amino acid residues Val73 and His122 to inhibit enzyme activity. Phthalylsulfacetamide can be used for the research of Escherichia coli infection .
|
-
-
- HY-168500
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-16 (compound 18) is a sulfone containing metallo-β-lactamase inhibitor with an anti-bacterial activity. Metallo-β-lactamase-IN-16 inhibits NDM-1 (New Dehli metallo-β-lactamase-1), IMP-1 (imipenemase-1), VIM-1 (Verona integron-encoded metallo-β-lactamase), and VIM-2 with IC50 values of 0.16 nM, 0.23 nM, 0.31 nM and 1.0 nM, respectively .
|
-
-
- HY-12826
-
|
|
Beta-lactamase
Bcl-2 Family
Bacterial
|
Cancer
|
|
IMB-XH1 is an inhibitor of myeloid cell factor 1 (Mcl-1) . IMB-XH1 is a non-competitive Delhi metallo-β-lactamase (NDM-1) inhibitor. The IC50s of IMB-XH1 against metallo-β-lactamases NDM-1, IMP-4, ImiS and L1 are 0.4637 μM, 3.980 μM, 0.2287 μM and 1.158 μM, respectively .
|
-
-
- HY-146637
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
VIM-2-IN-1 (compound 1dj) is a β-lactamase inhibitor with antibacterial activities. VIM-2-IN-1 has moderate IC50 values of 23 µM, 48 µM and 231 µM for Verona integron-encoded metallo-β-lactamase (VIM-2), German imipenemase-1 (GIM-1) and New Delhi metallo-β-lactamase (NDM-1), respectively .
|
-
-
- HY-P1195
-
|
|
iGluR
|
Neurological Disease
|
|
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
|
-
-
- HY-143415
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-7 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.019 μM, 13.64 μM, 0.38 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-7 potentiate antibacterial activity of Meropenem against the Gram-negative bacterial strains .
|
-
-
- HY-143414
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-6 is a potent VIM-Type metallo-β-lactamase inhibitor with IC50s of 0.56 μM, 29.50 μM and 5.78 μM for VIM-2, VIM-1 and VIM-5. Metallo-β-lactamase-IN-6 displays potent synergistic antibacterial activity with Meropenem against engineered Escherichia coli strains and intractable clinically isolated Pseudomonas aeruginosa producing VIM-2 MBL .
|
-
-
- HY-163339
-
|
|
Beta-lactamase
|
Infection
|
|
Metallo-β-lactamase-IN-14 (Compound 17e) is a Metallo-β-Lactamase inhibitor. Metallo-β-lactamase-IN-14 shows inhibition activity against VIM-1 and VIM-2. Metallo-β-lactamase-IN-14 has antibacterial activity against Gram-negative (GN) bacteria and P. aeruginosa .
|
-
-
- HY-146165
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-8 (compound 17) is a potent, reversible and competitive broad-spectrum inhibitor of metallo-β-lactamases (MβLs), with IC50s of 1.3 μM, 5.7 μM, 9.8 μM, and 9.9 μM for L1, ImiS, IMP-1 and VIM-2, respectively. Metallo-β-lactamase-IN-8 exhibits antibacterial activity .
|
-
-
- HY-161094
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-12 is a dual inhibitor of metal β-lactamases (MβLs (NDM-1, IMP-1)) and serine β-lactamases (SβLs (OXA-48, KPC-2)), with IC50 values of 0.64 μM, 1.32 μM, 1.01 μM, and 0.57 μM, respectively. Metallo-β-lactamase-IN-12 has antibacterial activity .
|
-
-
- HY-144261
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-3 (compound 35) is a potent metallo-β-lactamases (MBL) inhibitor. Metallo-β-lactamase-IN-3 shows high activity against VIM-1 and NDM-1, with IC50 of 0.6 and 1.0 μM, respectively. Metallo-β-lactamase-IN-3 does not show inhibition of IMP-7 .
|
-
-
- HY-155504
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-11 (compound 5f) is a Metallo-β-lactamases (MBLs) inhibitor, potent against bacterial metallophyllactamase CphA (IC50=45 µM). Metallo-β-lactamase-IN-11 (10 µM) inhibits NDM-1 by 49% and AIM-1 by 61%. Metallo-β-lactamase-IN-11 can be used in the research of inhibiting antibiotic resistance .
|
-
-
- HY-152105
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-9 (Compound 23) is a pan metallo-beta-lactamase (MBL) inhibitor with IC50s of 35, 269 and 369 nM against NDM-1, VIM-1 and IMP-1, respectively .
|
-
-
- HY-117951
-
|
|
Beta-lactamase
|
Infection
|
|
ANT431 is a metallo-β-lactamase inhibitor that also restores the effectiveness of Meropenem (HY-13678) in a mouse thigh Escherichia coli infection model .
|
-
-
- HY-144259
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.1 μM (VIM-1), 1.3 μM (NDM-1), and 5.0 μM (IMP-7), respectively .
|
-
-
- HY-144262
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Metallo-β-lactamase-IN-4 (compound 40) is a potent metallo-β-lactamases (MBL) inhibitor, with IC50 values of 0.5 μM (VIM-1), 2.1 μM (NDM-1), and 3.3 μM (IMP-7), respectively .
|
-
-
- HY-155283
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
Zndm19 is a New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor. Zndm19 can be used for the research of drug-resistant bacterial infections .
|
-
-
- HY-P10768A
-
|
|
PACAP Receptor
|
Inflammation/Immunology
|
|
Ro 25-1553 TFA is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 TFA exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .
|
-
-
- HY-P3100
-
|
|
Parasite
|
Infection
|
|
Orfamide A is a major metabolite of insecticidal biosurfactant in Pseudomonas sp. F6 and has aphidicidal activity. Orfamide A can be used for aphid control in organic agriculture. Orfamide A exhibits dose-dependent mortality against aphids with an LC50 value of 34.5 μg/mL .
|
-
-
- HY-P1209A
-
|
|
Melanocortin Receptor
|
Metabolic Disease
|
|
PG106 TFA is a potent and selective human melanocortin 3 (hMC3) receptor antagonist (IC50= 210 nM) and has noactivity at hMC4 receptors (EC50=9900 nM) and hMC5 receptor .
|
-
-
- HY-161310
-
|
|
Beta-lactamase
|
Infection
|
|
Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC50 values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .
|
-
-
- HY-13271B
-
|
TSA TFA
|
HDAC
Autophagy
Apoptosis
|
Cancer
|
|
Tubastatin A (TSA) TFA is a potent and selective?HDAC6?inhibitor with?IC50?of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A TFA also inhibits HDAC10 and metallo-β-lactamase domain-containing protein?2 (MBLAC2).
|
-
-
- HY-178019
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1-IN-10 (Compound CS-23) is an irreversible and covalent New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 36 nM. NDM-1-IN-10 shows a synergistic effect with Meropenem (HY-13678) against NDM-1-expressing E. coli ( MIC of 0.25 μg/mL for E. coli BL21/pET15b-blaNDM-1). NDM-1-IN-10 can be used for bacterial infections research .
|
-
-
- HY-149929
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
EBL-3183, an indole-2-carboxylate, is a potent metallo-β-lactamase (MBL) inhibitor. EBL-3183 is reversibly binding, non-covalent, competitive NDM-1 inhibitor with a pIC50 of 7.7 .
|
-
-
- HY-176565
-
|
|
Beta-lactamase
|
Infection
|
|
ZN148 is a zinc-chelating synthetic metallo-β-lactamase (MBL) inhibitor which attenuates MBL-mediated carbapenem resistance. ZN148 can restore the in vitro clinical susceptibility to carbapenems in >98% of a large international collection of MBL-producing clinical Enterobacterales strains. ZN148 can be utilized in research on anti MBL-producing bacteria .
|
-
-
- HY-178976
-
|
|
Beta-lactamase
|
Infection
|
|
YL6113 is a potent and selective dual inhibitor of metallo-β-lactamases (MBLs) and serine-β-lactamases (SBLs). YL6113 shows inhibitory effect to MBLs, such as NDm-1, VIM-2, IMP-1, with IC50 values of 0.25, 27.16 and 3.55 μM. YL6113 shows inhibitory effect to SBLs, such as KPC-2, AmpC, OXA-48, with IC50 values of 0.2, 34.1 and 1.31 μM. YL6113 enhances the antibacterial efficacy of Meropenem (HY-13678) against carbapenem-resistant Gram-negative bacteria. YL6113 can be used for the research of infection .
|
-
-
- HY-155202
-
-
-
- HY-162174
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
MBL-IN-2 ((2R, 2R')-5αC) is an inhibitor of Metallo-β-lactamase (MBL) that can inhibit New Delhi Metallo-β-lactamase-1 (NDM-1) with an IC50 of 0.3 μM. MBL-IN-2 ((2R, 2R')-5αC) can be used for the study of resistance to β-lactam antibiotics .
|
-
-
- HY-150758
-
-
- HY-P2064
-
|
|
Bacterial
|
Infection
|
|
Lariatins is a novel anti-mycobacterial peptides with a lasso structure produced by Rhodococcus jostii K01-B0171 .
|
-
- HY-P0007
-
|
Carbocalcitonin
|
Drug Intermediate
|
Metabolic Disease
|
|
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
|
-
- HY-P2120
-
|
|
Bacterial
|
Others
|
|
Pseudobactin A is a non-fluorescent extracellular iron carrier produced by the plant growth-promoting bacterium Pseudomonas B10 .
|
-
- HY-P10768
-
|
|
PACAP Receptor
|
Inflammation/Immunology
|
|
Ro 25-1553 is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 can be used for the study of bronchoconstriction .
|
-
- HY-105246
-
|
|
Beta-lactamase
HDAC
Apoptosis
|
Cancer
|
|
Pracinostat dihydrochloride is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat dihydrochloride also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
|
-
- HY-P1193
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
GR 82334 is a potent and specific reversible tachykinin NK1 receptor antagonist . GR 82334 inhibits substance P-induced sensitization by blocking SP NK1 receptors in naked mole-rats .
|
-
- HY-P2123A
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Colistin A sulfate hydrate is a major component of Colistin. Colistin is a polymyxin antibiotic and can be used to combat infections caused by problematic gram-negative bacteria .
|
-
- HY-P4910
-
|
|
Proteasome
Apoptosis
|
Cancer
|
|
Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .
|
-
- HY-P1209
-
-
- HY-13428R
-
|
|
Beta-lactamase
HDAC
Virus Protease
|
Cancer
|
|
Tubacin (Standard) is the analytical standard of Tubacin. This product is intended for research and analytical applications. Tubacin is a potent and selective inhibitor of HDAC6, with an IC50 value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
- HY-144100
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
β-Lactamase-IN-7 (compound 14) is a potent VIM-Type metallo-β-lactamase inhibitor, with Kis of 1.26 μM and 0.54 μM for VIM-1 and VIM-4, respectively. β-Lactamase-IN-7 can effectively inhibit Klebsiella pneumoniae .
|
-
- HY-13322R
-
|
SB939 (Standard)
|
Beta-lactamase
HDAC
Apoptosis
Reference Standards
|
Cancer
|
|
Pracinostat (Standard) is the analytical standard of Pracinostat. This product is intended for research and analytical applications. Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC50s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC50 below 10 nM .
|
-
- HY-B0368A
-
|
SQ 14225 hydrochloride
|
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril (SQ 14225) hydrochloride, antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril hydrochloride is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-13271AR
-
|
|
Beta-lactamase
HDAC
Autophagy
Apoptosis
|
Cancer
|
|
Tubastatin A (Standard) is the analytical standard of Tubastatin A. This product is intended for research and analytical applications. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
- HY-13271R
-
|
Tubastatin A HCl (Standard); TSA HCl (Standard)
|
Beta-lactamase
HDAC
Autophagy
Apoptosis
Reference Standards
|
Cancer
|
|
Tubastatin A (Hydrochloride) (Standard) is the analytical standard of Tubastatin A (Hydrochloride). This product is intended for research and analytical applications. Tubastatin A Hydrochloride (Tubastatin A HCl) is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A Hydrochloride also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
- HY-162493
-
|
|
Bacterial
|
Infection
|
|
MBL-IN-3 (compound 72922413) is a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor(IC50=54±4 μM). MBL-IN-3 is identified and shown to lower minimum inhibitory concentrations (MICs) of Meropenem (HY-13678) for a panel of E. coli and K. pneumoniae clinical isolates expressing NDM-1. MBL-IN-3 can be used for antibiotic sensitizer research .
|
-
- HY-B0368S
-
|
SQ 14225-d3
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
|
|
Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-168861
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1 inhibitor-8 (Compound 18b) is the covalent inhibitor for new delhi metallo-β-lactamase-1 (NDM-1) with an IC50 of 7.03 μM. NDM-1 inhibitor-8 inhibits the drug resistant strains, exhibits synergistic antibacterial effect with the use of Meropenem (HY-13678). NDM-1 inhibitor-8 exhibits anti-infectious activity in mouse models .
|
-
- HY-110061
-
|
|
HDAC
Virus Protease
Beta-lactamase
|
Infection
|
|
(2R,4R,6S)-Tubacin is the 2R,4R,6S enantiomer of Tubacin (HY-13428). Tubacin is a potent and selective inhibitor of HDAC6, with an IC50 value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
|
-
- HY-173472
-
|
|
Bacterial
Beta-lactamase
|
Infection
|
|
MBL-IN-5 is a metallo-β-lactamase (MBL) inhibitor. MBL-IN-5 inhibits three clinically relevant B1 subfamily MBLs (NDM-1, VIM-1, and IMP-1) with IC50s of 0.05 nM, 14 nM and 21 nM respectively. MBL-IN-5 remarkably enhances carbapenems’ effectiveness against MBL-producing clinical strains and significantly reduces the bacterial load in a neutropenic murine thigh infection model combined with the IPM antibiotic .
|
-
- HY-118013
-
|
|
Bacterial
|
Infection
|
|
NDM-1 inhibitor-2 is an inhibitor of New Delhi metallo-β-lactamase-1 (NDM-1) and has the ability to inhibit NDM-1 activity. NDM-1 inhibitor-2 exhibits a good inhibitory effect on drug-resistant bacterial strains that overexpress NDM-1. When NDM-1 inhibitor-2 is used in combination with the carbapenem antibiotic meropenem, a favorable synergistic effect can be produced .
|
-
- HY-13271AG
-
|
|
HDAC
Beta-lactamase
Autophagy
Apoptosis
|
Cancer
|
|
Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
- HY-B0368S1
-
|
SQ 14225-13C5,15N
|
Isotope-Labeled Compounds
Angiotensin-converting Enzyme (ACE)
|
Cardiovascular Disease
Cancer
|
|
Captopril- 13C5, 15N (SQ 14225- 13C5, 15N) is 13C and 15N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
- HY-113590
-
|
|
Bacterial
|
Infection
|
|
FR295389 is a dihydroimidazopyrazolium cephalosporin with antibacterial activity. FR295389 shows activity against IMP-type metallo-β-lactamases (MBL)-producing Klebsiella pneumoniae, Acinetobacter baumanii and Pseudomonas putida with MIC values ranging from 4 to 32 mg/mL .
|
-
- HY-175724
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
MBL-IN-6 (Compound 6d) is a Metallo-β-lactamase (MBL) inhibitor with Kis of 2.6 and 0.08 μM for NDM-1 and VIM-2, respectively. MBL-IN-6 has a synergistic activities with Imipenem (HY-B1369A) on MBL-producing clinical isolates (such as E. coli SI-M001, K. pneumonia T2301 and S. marcescens SI-1591) with MICs of 2-64 μg/mL. MBL-IN-6 does not have off-target effects without ACE-1 inhibition activity. MBL-IN-6 can be used for antimicrobial resistance research .
|
-
- HY-121765R
-
|
N,S-Diacetyl-L-cysteine (Standard)
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
|
Dacisteine (Standard) is the analytical standard of Dacisteine. This product is intended for research and analytical applications. Dacisteine (N,S-Diacetyl-L-cysteine) is a cysteine derivative and displays a less New Delhi metallo-beta-lactamase-1 (NDM-1) inhibitor with an IC50 value of 1000 μM . Dacisteine can be used for the treatment of cardiovascular and cerebrovascular diseases caused by platelet aggregation .
|
-
- HY-B0368C
-
|
epi-D-SQ 14225
|
Beta-lactamase
|
Infection
|
|
epi-D-Captopril (epi-D-SQ 14225) is a stereoisomer of Captopril (HY-B0368) and an inhibitor of metallo-β-lactamases (MBLs). The IC50 values of epi-D-Captopril against NDM-1, IMP-1, and VIM-2 are 64 μM, 173 μM, and 5.5 μM, respectively. epi-D-Captopril is expected to be used in the research of diseases caused by MBLs-related drug-resistant bacterial infections .
|
-
- HY-129200
-
|
|
Endogenous Metabolite
|
Others
|
|
Aspergillomarasmine A is a natural aminopolycarboxylic acid with potent inhibitory activity against class B metallo-β-lactamases (MBLs). Aspergillomarasmine A inactivates MBLs by removing a catalytic Zn2+ cofactor. Aspergillomarasmine A acts as a selective Zn2+ scavenger, promoting the dissociation of the metal cofactor, thereby indirectly inactivating NDM-1. Aspergillomarasmine A causes the loss of Zn2+ ions from the low-affinity binding site of NDM-1. The action of Aspergillomarasmine A results in the rapid degradation of Zn2+-deficient NDM-1, thereby enhancing its potency as a β-lactam enhancer. The mechanism of Aspergillomarasmine A has broad applicability among different Zn2+ chelators .
|
-
- HY-155104
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
MBL-IN-1 (compound 41) is a β-Lactamase inhibitor, with the IC50 ranging from 0.10 to 25.85 µM. MBL-IN-1 can be used for research of bacterial infections .
|
-
- HY-128049
-
|
|
Beta-lactamase
|
Infection
|
|
ML121 is a selective and potent VIM-2 inhibitor with an IC50 of 54 nM and a Ki of 148 nM. ML121 shows inactive in IMP-1 and TEM-1 beta-lactamase assays. ML121 can potentiate the antibiotic activity of Imipenem (HY-B1369A) in VIM-2 transformed E.coli .
|
-
- HY-W140346
-
|
|
Environmental Pollutants
Beta-lactamase
|
Infection
Cancer
|
|
Copper (II) pyrithione is a New Delhi metallo-β-lactamase 1 inhibitor. Copper (II) pyrithione inhibits New Delhi metallo-β-lactamase 1 via transmetallation of its zinc (II) cofactor with copper (II). Copper (II) pyrithione exerts cytotoxic effects on pancreatic cancer cells and osteosarcoma cells. Copper (II) pyrithione exhibits antibacterial activity against Gram-positive bacteria and some Gram-negative bacteria. Copper (II) pyrithione can synergistically enhance the activity of β-lactam antibiotics against β-lactam-resistant bacteria. Copper (II) pyrithione can be used in studies related to pancreatic cancer, osteosarcoma and bacterial infections .
|
-
- HY-P1195A
-
|
|
iGluR
|
Neurological Disease
|
|
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
|
-
- HY-W002684
-
|
|
Beta-lactamase
|
Others
|
|
(S)-2-Benzylsuccinic acid is an intermediate of KAD-1229 (HY-B0682A). (S)-2-Benzylsuccinic acid exerts weak inhibitory activity against IMP-1 metallo-β-lactamase .
|
-
- HY-P10135
-
|
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
RES-701-1 is a cyclic peptide composed of 16 common L-amino acids, acting as a specific antagonist for the ETB receptor. RES-701-1 can inhibit the binding of 125I-ET-1 (125I-labeled Endothelin (ET)-1) to the ETB receptor, with an IC50 value of 10 nM .
|
-
- HY-P1208A
-
|
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
PG-931 TFA, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R(IC50=2.4 nM). PG-931 TFA can reverse haemorrhagic shock and prevent multiple organ damage in vivo .
|
-
- HY-P5568
-
|
RP 71955
|
HIV
|
Infection
|
|
RP 71955 is an antimicrobial peptide against HIV-1 .
|
-
- HY-P2202
-
|
|
Bacterial
|
Others
|
|
Desferriferribactin is a cyclic peptide containing a thirteen-membered ring. Desferriferribactin is a precursor of pyoverdins .
|
-
- HY-P11232
-
|
|
Toll-like Receptor (TLR)
Bacterial
|
Infection
|
|
NAB815 is a specific inhibitor of the Stx2a (Kd = 0.01 μM)/TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC50 = 0.057 μg/mL). NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice). NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS) .
|
-
- HY-100871R
-
|
|
Beta-lactamase
HDAC
Reference Standards
Apoptosis
|
Cancer
|
|
WT-161 (Standard) is the analytical standard of WT-161 (HY-100871). This product is intended for research and analytical applications. WT-161 is a potent and selective HDAC6 inhibitor with an IC50 of 0.40 nM . WT-161 also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) .
|
-
- HY-179709
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1-IN-12 (Compound 10c) is an inhibitor of NDM-1 metallo-β-lactamase, with an IC50 value of 9 nM. NDM-1-IN-12 effectively reverses bacterial resistance to β-lactam antibiotics and shows an additive effect when used in combination with antibiotics and SBL inhibitors. NDM-1-IN-12 can be used in the research of anti-multi-drug resistant bacteria .
|
-
- HY-122262
-
|
|
Beta-lactamase
Bacterial
|
Infection
|
|
NDM-1-IN-6 (Compound 1) is a potent, selective and competitive New Delhi Metallo-β-lactamase-1 (NDM-1) inhibitor with a Ki of 0.72 μM. NDM-1-IN-6 has a synergistic antibacterial effect with the carbapenem antibiotic Meropenem (HY-13678). NDM-1-IN-6 is mainly used for research on NDM-1-mediated multidrug-resistant bacterial infections .
|
-
- HY-182058
-
|
|
Drug Derivative
Bacterial
Beta-lactamase
|
Infection
|
|
ATM potentiators-1 is a quercetin derivative that synergistically enhances the antibacterial activity of Aztreonam (ATM, HY-B0129) against metallo-β-lactamase-producing Pseudomonas aeruginosa. ATM potentiators-1 inhibits NDM-1, OXA-10, VIM-2, KPC-2, and OXA-48, suppressing the efflux pump activity of Pseudomonas aeruginosa. When used in combination with CCCP (HY-100941), it exhibits a synergistic inhibitory effect. ATM potentiators-1 is applicable to research related to Pseudomonas aeruginosa infections .
|
-
- HY-P4613
-
|
|
Drug Derivative
Drug Intermediate
|
Others
|
|
Fmoc-D-allo-Thr-OH is a derivative of D-allothreonine (HY-W001959), which is commonly used as a building block in solid-phase peptide synthesis (SPPS) .
|
-
- HY-B0368B
-
|
|
Beta-lactamase
Antibiotic
Bacterial
|
Infection
Inflammation/Immunology
|
|
D-Captopril is a NDM-1 inhibitor and a competitive BlaB inhibitor, with an IC50 value of 21.8 µM against NDM-1 and a Ki of 70-100 µM against BlaB. D-Captopril synergistically reduces the minimum inhibitory concentration of Meropenem (HY-13678) against NDM-1-expressing bacteria. D-Captopril binds to BcII via its thiolate sulfur atom and carboxylate group, altering metal ion occupancy and modulating Cd 2+ binding affinity. D-Captopril can be used in the research of neonatal meningitis, sepsis and bacterial infections .
|
-
- HY-P10768B
-
|
|
PACAP Receptor
|
Inflammation/Immunology
|
|
Ro 25-1553 acetate is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 acetate exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 acetate produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 acetate can be used for the study of bronchoconstriction .
|
-
- HY-P0267A
-
|
|
Melanocortin Receptor
|
Neurological Disease
Metabolic Disease
Endocrinology
|
|
Melanotan (MT)-II acetate is a melanocortin receptor agonist that crosses the blood-brain barrier. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction .
|
-
- HY-P2123S
-
-
- HY-P11022
-
|
A-3302-B
|
Endogenous Metabolite
HSV
TRP Channel
|
Infection
Cancer
|
|
TL-119 (A-3302-B) is a polypeptide. TL-119 can be isolated from the bacteria Micromonospora sp. MAG 9-7 and Saccharomonospora sp. CNQ-490. TL-119 inhibits TRPV-1. TL-119 exhibits antiviral activity against HSV-2. TL-119 possesses anticancer activity against gastric cancer and colorectal cancer .
|
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P11676
-
|
BRII-693; QPX9003
|
Antibiotic
Bacterial
|
Infection
|
|
Soralimixin (BRII-693), a Polymyxin derivative, is a next-generation intravenous (IV)-administered synthetic macrocyclic peptide antibiotic. Soralimixin can be used for the study of infections caused by drug-resistant Gram-negative pathogens .
|
-
- HY-P11607
-
|
|
Bacterial
|
Infection
|
|
CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection .
|
-
- HY-P2209
-
|
Daechuine S27; N-Demethylamphibine H
|
Parasite
Phosphodiesterase (PDE)
|
Infection
|
|
Nummularine B (Daechuine S27; N-Demethylamphibine H) is an anti-parasite agent. Nummularine B inhibits calmodulin-dependent phosphodiesterase activity with an IC50 of 16.8 μM. Nummularine B inhibits the growth of Plasmodium and Leishmania donovani in vitro. Nummularine B inhibits the calmodulin-dependent activity of actomyosin Ca 2+-ATPase. Nummularine B is applicable to research related to malaria and visceral leishmaniasis .
|
-
- HY-145632
-
|
ALT-801
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
- HY-A0248AS1
-
|
|
Isotope-Labeled Compounds
Bacterial
|
Infection
|
|
Polymyxin B1-D-Leu-d7 TFA is the deuterium labeled Polymyxin B1 (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
-
- HY-A0248A
-
|
|
Bacterial
|
Infection
|
|
Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
-
- HY-A0248AS
-
|
|
Isotope-Labeled Compounds
Bacterial
|
Infection
|
|
Polymyxin B1-d7 TFA is the deuterium labeled Polymyxin B1 TFA (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
-
- HY-P10447
-
|
Fengycin IX; SNA-60-367-3
|
Phospholipase
Fungal
|
Infection
|
|
Plipastatin A1 (Fengycin IX; SNA-60-367-3) is a lipopeptide with phospholipase A2 inhibitory activity. Plipastatin A1 inhibits conidial germination of Botrytis cinerea in vitro and reduces the incidence of gray mold on tomato leaves. Plipastatin A1 is applicable to research related to gray mold [1][2].
|
-
- HY-145632A
-
|
ALT-801 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-13271AG
-
|
|
Fluorescent Dyes
|
|
Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
| Cat. No. |
Product Name |
Type |
-
- HY-13271AG
-
|
|
Biochemical Assay Reagents
|
|
Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P0267
-
-
- HY-106178
-
PMX-53
Maximum Cited Publications
8 Publications Verification
3D53
|
Complement System
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
PMX-53 (3D53) is a synthetic peptidic and a potent and orally active complement C5a receptor (CD88) antagonist with an IC50 of 20 nM. PMX-53 is also a low-affinity MrgX2 agonist that stimulates MrgX2-mediated mast cell degranulation. PMX-53 specifically binds to C5aR1 and does not bind to the second C5aR (C5L2) and C3aR. PMX-53 has anti-inflammatory, anticancer and antiatherosclerotic effects .
|
-
- HY-18678A
-
|
PT-141 Acetate
|
Melanocortin Receptor
|
Metabolic Disease
|
|
Bremelanotide (PT-141) Acetate is a melanocortin receptor agonist. Bremelanotide Acetate can activate MC4R and increases dopamine release. Bremelanotide Acetate induces appetitive sexual behaviors, female mounting behavior, and repetitive self-grooming. Bremelanotide Acetate can be used for the research of hypoactive sexual desire disorders .
|
-
- HY-P0227
-
|
|
Melanocortin Receptor
|
Metabolic Disease
|
|
SHU 9119 is a potent human melanocortin 3 and 4 receptors (MC3/4R) antagonist and a partial MC5R agonist; with IC50 values of 0.23, 0.06, and 0.09 nM for human MC3R, MC4R and MC5R, respectively.
|
-
- HY-145632
-
|
ALT-801
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
- HY-A0248A
-
|
|
Bacterial
|
Infection
|
|
Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
-
- HY-P11290
-
-
- HY-P10447
-
|
Fengycin IX; SNA-60-367-3
|
Phospholipase
Fungal
|
Infection
|
|
Plipastatin A1 (Fengycin IX; SNA-60-367-3) is a lipopeptide with phospholipase A2 inhibitory activity. Plipastatin A1 inhibits conidial germination of Botrytis cinerea in vitro and reduces the incidence of gray mold on tomato leaves. Plipastatin A1 is applicable to research related to gray mold [1][2].
|
-
- HY-W101299
-
|
|
Amino Acid Derivatives
|
Metabolic Disease
|
|
N-Acetyl-D-allo-isoleucine is an amino acid derivative. N-Acetyl-D-allo-isoleucine is promising for research of amino acid metabolism, such as abnormal isoleucine metabolism .
|
-
- HY-P1208
-
|
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
PG-931, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R (IC50=2.4 nM). PG-931 can reverse haemorrhagic shock and prevent multiple organ damage in vivo .
|
-
- HY-A0248AS
-
|
|
Isotope-Labeled Compounds
Bacterial
|
Infection
|
|
Polymyxin B1-d7 TFA is the deuterium labeled Polymyxin B1 TFA (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
-
- HY-145632A
-
|
ALT-801 TFA
|
GLP Receptor
GCGR
|
Metabolic Disease
|
|
Pemvidutide (ALT-801) TFA is a GLP-1R/GCGR dual agonist, shows striking reductions in body weight, liver fat and serum lipids. Pemvidutide TFA can be used in non-alcoholic steatohepatitis (NASH) and obesity research .
|
-
- HY-P1195
-
|
|
iGluR
|
Neurological Disease
|
|
PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
|
-
- HY-P10278
-
|
|
Peptides
|
Endocrinology
|
|
Anantin binds competitively to the receptor of atrial natriuretic factor (ANF) from bovine adrenal cortex (Kd = 0.6 μM) and acts as natriuretic peptide receptor A antagonist .
|
-
- HY-P10768A
-
|
|
PACAP Receptor
|
Inflammation/Immunology
|
|
Ro 25-1553 TFA is a 31 amino acid vasoactive intestinal peptide (VIP) analog, that acts as an agonist for VIP2 receptor (VPAC2 receptor). Ro 25-1553 TFA exhibits a bronchodilator effect in nerve-induced or Carbachol (HY-B1208)-induced tracheal smooth muscle contraction in guinea pig model .
|
-
- HY-P3100
-
|
|
Parasite
|
Infection
|
|
Orfamide A is a major metabolite of insecticidal biosurfactant in Pseudomonas sp. F6 and has aphidicidal activity. Orfamide A can be used for aphid control in organic agriculture. Orfamide A exhibits dose-dependent mortality against aphids with an LC50 value of 34.5 μg/mL .
|
-
- HY-P1209A
-
|
|
Melanocortin Receptor
|
Metabolic Disease
|
|
PG106 TFA is a potent and selective human melanocortin 3 (hMC3) receptor antagonist (IC50= 210 nM) and has noactivity at hMC4 receptors (EC50=9900 nM) and hMC5 receptor .
|
-
- HY-P2064
-
|
|
Bacterial
|
Infection
|
|
Lariatins is a novel anti-mycobacterial peptides with a lasso structure produced by Rhodococcus jostii K01-B0171 .
|
-
- HY-P0007
-
|
Carbocalcitonin
|
Drug Intermediate
|
Metabolic Disease
|
|
Elcatonin (Carbocalcitonin) is a synthetic analog of eel calcitonin. Elcatonin increases bone mineral density, inhibits bone resorption and processes a central analgesic effect .
|
-
- HY-P2120
-
|
|
Bacterial
|
Others
|
|
Pseudobactin A is a non-fluorescent extracellular iron carrier produced by the plant growth-promoting bacterium Pseudomonas B10 .
|
-
- HY-P10768
-
|
|
PACAP Receptor
|
Inflammation/Immunology
|
|
Ro 25-1553 is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 can be used for the study of bronchoconstriction .
|
-
- HY-P1193
-
|
|
Neurokinin Receptor
|
Neurological Disease
|
|
GR 82334 is a potent and specific reversible tachykinin NK1 receptor antagonist . GR 82334 inhibits substance P-induced sensitization by blocking SP NK1 receptors in naked mole-rats .
|
-
- HY-P2123A
-
|
|
Bacterial
Antibiotic
|
Infection
|
|
Colistin A sulfate hydrate is a major component of Colistin. Colistin is a polymyxin antibiotic and can be used to combat infections caused by problematic gram-negative bacteria .
|
-
- HY-P4910
-
|
|
Proteasome
Apoptosis
|
Cancer
|
|
Baceridin is a proteasome inhibitor and a cyclic hexapeptide. Baceridin can be isolated from the culture medium of Epiphytic Bacillus. Baceridin can inhibit cell cycle progression and induce tumor cell apoptosis through a p53-independent pathway. Baceridin can be used in cancer research .
|
-
- HY-P1209
-
-
- HY-P1195A
-
|
|
iGluR
|
Neurological Disease
|
|
PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
|
-
- HY-P10135
-
|
|
Endothelin Receptor
|
Cardiovascular Disease
|
|
RES-701-1 is a cyclic peptide composed of 16 common L-amino acids, acting as a specific antagonist for the ETB receptor. RES-701-1 can inhibit the binding of 125I-ET-1 (125I-labeled Endothelin (ET)-1) to the ETB receptor, with an IC50 value of 10 nM .
|
-
- HY-P1208A
-
|
|
Melanocortin Receptor
|
Inflammation/Immunology
|
|
PG-931 TFA, an analog of SHU 9119 (HY-P0227), is a potent melanocortin 4 (MC4) receptor (IC50=0.58 nM) agonist and is more selective than for the hMC3R (IC50=55 nM) or the hMC5R(IC50=2.4 nM). PG-931 TFA can reverse haemorrhagic shock and prevent multiple organ damage in vivo .
|
-
- HY-P5568
-
|
RP 71955
|
HIV
|
Infection
|
|
RP 71955 is an antimicrobial peptide against HIV-1 .
|
-
- HY-P2202
-
|
|
Bacterial
|
Others
|
|
Desferriferribactin is a cyclic peptide containing a thirteen-membered ring. Desferriferribactin is a precursor of pyoverdins .
|
-
- HY-P11232
-
|
|
Toll-like Receptor (TLR)
Bacterial
|
Infection
|
|
NAB815 is a specific inhibitor of the Stx2a (Kd = 0.01 μM)/TLR4 interaction. NAB815 inhibits the neutrophil/Stx2a interaction (IC50 = 0.057 μg/mL). NAB815 inhibits the formation of Stx2-containing extracellular vesicles (EVs) produced by leukocytes and platelets and reduces their toxic effects in cellular (Vero cells) and animal models (CD-1 mice). NAB815 reduces bacterial loads in the kidneys, urine, and bladders of Escherichia coli-infected mice. NAB815 is useful in the study of hemolytic uremic syndrome (HUS) .
|
-
- HY-P4613
-
|
|
Drug Derivative
Drug Intermediate
|
Others
|
|
Fmoc-D-allo-Thr-OH is a derivative of D-allothreonine (HY-W001959), which is commonly used as a building block in solid-phase peptide synthesis (SPPS) .
|
-
- HY-P10768B
-
|
|
PACAP Receptor
|
Inflammation/Immunology
|
|
Ro 25-1553 acetate is a selective VIP2 receptor (VPAC2 receptor) agonist. Ro 25-1553 acetate exhibits bronchodilatory effects on tracheal smooth muscle contractions induced by nerve stimulation or Carbachol (HY-B1208). Ro 25-1553 acetate produces a superimposed effect when combined with Formoterol and Salmeterol (HY-14302). Ro 25-1553 acetate can be used for the study of bronchoconstriction .
|
-
- HY-P0267A
-
|
|
Melanocortin Receptor
|
Neurological Disease
Metabolic Disease
Endocrinology
|
|
Melanotan (MT)-II acetate is a melanocortin receptor agonist that crosses the blood-brain barrier. Melanotan (MT)-II acetate activates melanocortin receptor 3 and melanocortin receptor 4, and stimulates the release of central endogenous oxytocin. Melanotan (MT)-II acetate reverses recognition memory impairment, increased anxiety levels and reduced exploratory tendency in zebrafish exposed to short-term high-fat diet. Melanotan (MT)-II acetate improves impaired social behavior indicators in mouse models of autism spectrum disorder. Melanotan (MT)-II acetate induces weight loss, reduces food intake and exerts anorectic effects. Melanotan (MT)-II acetate increases intracavernous pressure and erectile activity in brown rats. Melanotan (MT)-II acetate can be used in studies related to memory impairment, anxiety, reduced exploratory behavior, autism spectrum disorder, obesity and erectile dysfunction .
|
-
- HY-P2123S
-
-
- HY-P11022
-
|
A-3302-B
|
Endogenous Metabolite
HSV
TRP Channel
|
Infection
Cancer
|
|
TL-119 (A-3302-B) is a polypeptide. TL-119 can be isolated from the bacteria Micromonospora sp. MAG 9-7 and Saccharomonospora sp. CNQ-490. TL-119 inhibits TRPV-1. TL-119 exhibits antiviral activity against HSV-2. TL-119 possesses anticancer activity against gastric cancer and colorectal cancer .
|
-
- HY-P11596
-
|
|
Integrin
|
Cancer
|
|
NOTA-Asp2-αvβ6L is an integrin αvβ6 binder with selective accumulation in αvβ6-positive pancreatic cancer cells and tumors. NOTA-Asp2-αvβ6L can be used as a PET/CT tracer for imaging pancreatic ductal adenocarcinoma (PDAC) .
|
-
- HY-P11676
-
|
BRII-693; QPX9003
|
Antibiotic
Bacterial
|
Infection
|
|
Soralimixin (BRII-693), a Polymyxin derivative, is a next-generation intravenous (IV)-administered synthetic macrocyclic peptide antibiotic. Soralimixin can be used for the study of infections caused by drug-resistant Gram-negative pathogens .
|
-
- HY-P11607
-
|
|
Bacterial
|
Infection
|
|
CyLip-10 is a microbial-derived cyclic-lipid antimicrobial peptide. CyLip-10 has broad-spectrum antimicrobial efficacy, low hemolytic activity, and excellent stability. CyLip-10 can disrupt membrane integrity, inhibit biofilm formation and induce membrane permeabilization and bacterial cell death. CyLip-10 reduces bacterial load, promotes wound healing, and alleviates inflammatory responses in a mouse Methicillin (HY-121544)-resistant Staphylococcus aureus skin wound infection model. CyLip-10 can be used for the bacterial infection .
|
-
- HY-P2209
-
|
Daechuine S27; N-Demethylamphibine H
|
Parasite
Phosphodiesterase (PDE)
|
Infection
|
|
Nummularine B (Daechuine S27; N-Demethylamphibine H) is an anti-parasite agent. Nummularine B inhibits calmodulin-dependent phosphodiesterase activity with an IC50 of 16.8 μM. Nummularine B inhibits the growth of Plasmodium and Leishmania donovani in vitro. Nummularine B inhibits the calmodulin-dependent activity of actomyosin Ca 2+-ATPase. Nummularine B is applicable to research related to malaria and visceral leishmaniasis .
|
-
- HY-A0248AS1
-
|
|
Isotope-Labeled Compounds
Bacterial
|
Infection
|
|
Polymyxin B1-D-Leu-d7 TFA is the deuterium labeled Polymyxin B1 (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-A0248AS
-
|
|
|
Polymyxin B1-d7 TFA is the deuterium labeled Polymyxin B1 TFA (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
-
-
- HY-B0368S
-
|
|
|
Captopril-d3 is deuterium labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-B0368S1
-
|
|
|
Captopril- 13C5, 15N (SQ 14225- 13C5, 15N) is 13C and 15N labeled Captopril. Captopril (SQ 14225), antihypertensive agent, is a thiol-containing competitive, orally active angiotensin-converting enzyme (ACE) inhibitor (IC50=0.025 μM) and has been widely used for research of hypertension and congestive heart failure. Captopril is also a New Delhi metallo-β-lactamase-1 (NDM-1) inhibitor with an IC50 of 7.9 μM .
|
-
-
- HY-P2123S
-
-
-
- HY-A0248AS1
-
|
|
|
Polymyxin B1-D-Leu-d7 TFA is the deuterium labeled Polymyxin B1 (HY-A0248A). Polymyxin B1 is a potent antimicrobial lipopeptide first derived from Bacilus polymyxa. Polymyxin B1 is the major component in Polymyxin B (HY-A0248). Polymyxin B1 can induce lysis of bacterial cells through interaction with their membranes. Polymyxin B1 has the potential for multidrug-resistant Gram-negative bacterial infections treatment .
|
-
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-13271AG
-
|
|
HDAC
Beta-lactamase
Autophagy
Apoptosis
|
Cancer
|
|
Tubastatin A (GMP) is the Tubastatin A (HY-13271A) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Tubastatin A is a potent and selective HDAC6 inhibitor with an IC50 of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: